Pharmaceuticals company Sai Life Science announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations was Rs 580 crore for Q4FY25 compared to Rs 439 crore in Q4FY24, an increase of 32% EBITDA stood at Rs 161 crore. for Q4FY25 compared to Rs 124 crore. in Q4FY24, an increase of 30% PAT stood at Rs 88 crore. for Q4FY25 compared to Rs 56 crore. in Q4FY24, an increase of 57% FY25 Financial Highlights: Revenue from Operations was Rs 1,695 crore for FY25 compared to Rs 1,465 crore in FY24, an increase of 16% EBITDA stood at Rs 425 crore. for FY25 compared to Rs 300 crore in FY24. an increase of 42% PAT stood at Rs 170crore. for FY25 compared to Rs 83 crore in FY24, an increase of 105% Commenting on the performance during the quarter, Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences, said, “We are pleased to report a strong performance for FY25, ably supported by solid execution, capacity expansion, and deeper engagement with our customers. Our integrated CRDMO model continues to add value, helping us deliver seamless solutions across the drug development lifecycle to our global and biotech partners. One of the highlights of the year was the launch of our Peptide Research Centre, set up to meet the growing demand for complex peptide synthesis and conjugation. This investment marks another step forward in strengthening our capabilities to support next-generation therapeutics. With India emerging as a strategic hub in global drug development, Sai Life Sciences is well-positioned to tap into new growth opportunities. We remain focused on investing in technology, infrastructure, and talent to stay aligned with the evolving needs of our clients. As we step into FY26, our priorities remain clear - to expand our capabilities, improve execution, and deliver lasting value to our stakeholders.” Siva Chittor, Director and Chief Financial Officer, Sai Life Sciences added, ” We are pleased to report a strong FY25 performance, driven by consistent momentum across our CDMO and CRO segments. Revenue grew by 16% and our EBITDA margin expanded to 25%, in line with our growth aspirations. Profit after tax grew by 105%, supported by stable finance costs and operating leverage. With the completion of our planned Rs 720 crore debt repayment, we have significantly strengthened our balance sheet and expect lower interest costs starting FY26. Capex for the year stood at Rs 408 crore, focused on enhancing our manufacturing footprint and expanding discovery capabilities. We remain committed to disciplined execution and prudent capital allocation as we continue to build on our growth momentum and deliver long-term value to stakeholders.” Result PDF